Liangzhong Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liangzhong Sun has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
Haiyan Wang
15 shared publicationsZhihui Yue
15 shared publicationsHuamu Chen
Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
12 shared publicationsMin Li
Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
9 shared publicationsHongrong Lin
Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
8 shared publicationsTing Liu
Department of Pediatrics, Longgang Central Hospital of Shenzhen, 1228 Shenhui Road, Shenzhen, Guangdong 518116, China
7 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Springer Nature in Pediatric Rheumatology
Secukinumab in the management of generalized pustular psoriasis comorbidity with nephrotic syndrome in a toddler with IL36RN variant
Purpose: To summarize the clinical feature, genetic variants of IL-36RN and biologic agent therapy in a toddler with generalized pustular psoriasis (GPP) with literature review. Methods: Clinical data, family history, urine samples, and skin biopsy specimens were collected. Gene sequencing was performed. IL-36Ra expression in urine cells and skin was detected by Western blotting and immunofluorescence staining, respectively. Results: A 1.5-year-old girl presented with eyelid and lower limb edema, her urine protein was 3+. Nephrotic syndrome was diagnosed, which was steroid-responsive but in a frequently relapse. At 1 year 9 months, red, ring-shaped plaques with silvery-white scales appeared on her trunk, later extending to face, limbs, and perineum, with development of pinpoint pustules. Inflammatory markers (erythrocyte sedimentation rate, C-reactive protein, interleukin-6 and tumor necrosis factor-α) were markedly elevated. Whole-exome sequencing identified a homozygous variant of IL36RN (c.115 + 6T > C). Her mother was a heterozygous carrier, while her father had homozygous variant as well and presented with toe skin lesions and nail damage since his young age. Protein analysis indicated absent IL-36Ra expression in skin and reduced expression in urinary epithelial cells. Erythema and pustules resolved after the administration of secukinumab at 2 years and 2 months of age. Conclusion: We report a case of GPP with a co-morbidity disease of idiopathic nephrotic syndrome in a toddler who harbored a homozygous IL36RN variant. Reduced IL-36Ra expression was evidenced in the involved skin and urine cells. The IL‑17 inhibitor appeared to be associated with clinical improvement in GPP-related manifestations. Clinical trial number: Not applicable.
- 14 September 2026
- Published by Springer Nature in Pediatric Rheumatology
Open AccessSecukinumab in the management of generalized pustular psoriasis comorbidity with nephrotic syndrome in a toddler with IL36RN variant
Purpose: To summarize the clinical feature, genetic variants of IL-36RN and biologic agent therapy in a toddler with generalized pustular psoriasis (GPP) with literature review. Methods: Clinical data, family history, urine samples, and skin biopsy specimens were collected. Gene sequencing was performed. IL-36Ra expression in urine cells and skin was detected by Western blotting and immunofluorescence staining, respectively. Results: A 1.5-year-old girl presented with eyelid and lower limb edema, her urine protein was 3+. Nephrotic syndrome was diagnosed, which was steroid-responsive but in a frequently relapse. At 1 year 9 months, red, ring-shaped plaques with silvery-white scales appeared on her trunk, later extending to face, limbs, and perineum, with development of pinpoint pustules. Inflammatory markers (erythrocyte sedimentation rate, C-reactive protein, interleukin-6 and tumor necrosis factor-α) were markedly elevated. Whole-exome sequencing identified a homozygous variant of IL36RN (c.115 + 6T > C). Her mother was a heterozygous carrier, while her father had homozygous variant as well and presented with toe skin lesions and nail damage since his young age. Protein analysis indicated absent IL-36Ra expression in skin and reduced expression in urinary epithelial cells. Erythema and pustules resolved after the administration of secukinumab at 2 years and 2 months of age. Conclusion: We report a case of GPP with a co-morbidity disease of idiopathic nephrotic syndrome in a toddler who harbored a homozygous IL36RN variant. Reduced IL-36Ra expression was evidenced in the involved skin and urine cells. The IL‑17 inhibitor appeared to be associated with clinical improvement in GPP-related manifestations. Clinical trial number: Not applicable.
- Open Access
- 23 June 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2684840
Spatiotemporal dynamics of renal distal convoluted tubule dilatation and cyst formation in nephronophthisis type 1 mice
Nephronophthisis (NPH), a rare but serious ciliopathy, is the predominant genetic cause of end-stage kidney disease (ESKD) in children and adolescents. Renal tubular dilatation and cyst formation are key pathological features of NPH. The mechanisms underlying renal cystogenesis remain poorly understood. This study employed sex-balanced Nphp1 deletion gene knockout (Nphp1KO) mice at 8, 12, and 24 weeks of age to investigate the spatiotemporal dynamics of renal tubules and cyst development, aiming to identify the origins of renal cysts. Quantitative evaluation of cyst progression revealed a significant increase in cyst number from 8 to 12 weeks of age, but no substantial change from 12 to 24 weeks. Additionally, cyst size remained stable throughout the study period. Serial section tracing and segment-specific tubular marker analysis confirmed that these cysts originated from the distal convoluted tubule (DCT), which displayed segmental dilation while preserving anatomical connections with adjacent, morphologically normal DCT. 3D reconstruction revealed that renal cysts appeared either as a single or in a bead-like arrangement. We demonstrated that human renal cyst epithelial cells from patients with NPH1 also originate primarily from the DCT. This study provides critical experimental evidence of the histopathological features of renal cysts in NPH1, advancing our understanding of the pathogenesis of NPHP-associated tubular dilation and cystogenesis.
- 23 June 2026
- Published by Taylor & Francis in Renal Failure
- Vol. 48 (1) , 2684840
Open AccessSpatiotemporal dynamics of renal distal convoluted tubule dilatation and cyst formation in nephronophthisis type 1 mice
Nephronophthisis (NPH), a rare but serious ciliopathy, is the predominant genetic cause of end-stage kidney disease (ESKD) in children and adolescents. Renal tubular dilatation and cyst formation are key pathological features of NPH. The mechanisms underlying renal cystogenesis remain poorly understood. This study employed sex-balanced Nphp1 deletion gene knockout (Nphp1KO) mice at 8, 12, and 24 weeks of age to investigate the spatiotemporal dynamics of renal tubules and cyst development, aiming to identify the origins of renal cysts. Quantitative evaluation of cyst progression revealed a significant increase in cyst number from 8 to 12 weeks of age, but no substantial change from 12 to 24 weeks. Additionally, cyst size remained stable throughout the study period. Serial section tracing and segment-specific tubular marker analysis confirmed that these cysts originated from the distal convoluted tubule (DCT), which displayed segmental dilation while preserving anatomical connections with adjacent, morphologically normal DCT. 3D reconstruction revealed that renal cysts appeared either as a single or in a bead-like arrangement. We demonstrated that human renal cyst epithelial cells from patients with NPH1 also originate primarily from the DCT. This study provides critical experimental evidence of the histopathological features of renal cysts in NPH1, advancing our understanding of the pathogenesis of NPHP-associated tubular dilation and cystogenesis.
- Open Access
- 4 June 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (8)
Renal-Limited Thrombotic Microangiopathy in Infants: A Case Series
- 4 June 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (8)
Open AccessRenal-Limited Thrombotic Microangiopathy in Infants: A Case Series
- Open Access
- 10 March 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
HAND1 controls the lineage bifurcation of trophoblast and amnion from human pluripotent stem cells
Trophoblast and amniotic lineages, representing key extra-embryonic tissues, can be differentiated from human pluripotent stem cells (hPSCs) under chemically defined conditions. However, the regulatory mechanisms coordinating the fate decision between these lineages during PSC differentiation remain incompletely understood. Leveraging CRISPR/Cas9-mediated loss-of-function screening in lineage-reporter PSCs, we identified the transcription factor HAND1 as a critical determinant controlling the bifurcation of trophoblast and amniotic lineages. Genetic ablation of HAND1 effectively abrogated the amniotic differentiation capacity of PSCs while concomitantly enhancing their trophoblast differentiation potential. Conversely, ectopic HAND1 overexpression impaired trophoblast differentiation. Notably, forced HAND1 expression in human trophoblast stem cells (TSCs) induced transcriptional reprogramming toward an amniotic fate, indicating its lineage-instructive capability. Mechanistic analyses demonstrated that HAND1 interacts with the TCFs and Wnt signaling effectors β-catenin to form a transcriptional complex that antagonistically modulates the balance between trophoblast- and amnion-associated gene regulatory networks. Collectively, our findings establish HAND1 as a master regulator orchestrating the amniotic versus trophoblast lineage choice during human PSC differentiation, thereby illuminating fundamental regulatory mechanism underlying extra-embryonic lineage specification.
- 10 March 2026
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessHAND1 controls the lineage bifurcation of trophoblast and amnion from human pluripotent stem cells
Trophoblast and amniotic lineages, representing key extra-embryonic tissues, can be differentiated from human pluripotent stem cells (hPSCs) under chemically defined conditions. However, the regulatory mechanisms coordinating the fate decision between these lineages during PSC differentiation remain incompletely understood. Leveraging CRISPR/Cas9-mediated loss-of-function screening in lineage-reporter PSCs, we identified the transcription factor HAND1 as a critical determinant controlling the bifurcation of trophoblast and amniotic lineages. Genetic ablation of HAND1 effectively abrogated the amniotic differentiation capacity of PSCs while concomitantly enhancing their trophoblast differentiation potential. Conversely, ectopic HAND1 overexpression impaired trophoblast differentiation. Notably, forced HAND1 expression in human trophoblast stem cells (TSCs) induced transcriptional reprogramming toward an amniotic fate, indicating its lineage-instructive capability. Mechanistic analyses demonstrated that HAND1 interacts with the TCFs and Wnt signaling effectors β-catenin to form a transcriptional complex that antagonistically modulates the balance between trophoblast- and amnion-associated gene regulatory networks. Collectively, our findings establish HAND1 as a master regulator orchestrating the amniotic versus trophoblast lineage choice during human PSC differentiation, thereby illuminating fundamental regulatory mechanism underlying extra-embryonic lineage specification.
- 6 December 2025
- Published by Elsevier in Translational Research
- Vol. 285-286, 48-58
ZONAB regulates renal cyst formation in nphp1 knockout mice
- 6 December 2025
- Published by Elsevier in Translational Research
- Vol. 285-286, 48-58
ZONAB regulates renal cyst formation in nphp1 knockout mice
- Open Access
- 12 September 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (3) , 560-568
Mycophenolate Mofetil versus Cyclophosphamide for Initial Therapy in Childhood-Onset Proliferative Lupus Nephritis
Key Points: The total renal response rate in the mycophenolate mofetil group was found to be noninferior to that in the cyclophosphamide group. There was no significant difference in the incidence of adverse drug reactions between the mycophenolate mofetil and cyclophosphamide groups. The reduction in SLE Disease Activity Index scores was similar between the two groups. Background: Recent studies suggest that oral mycophenolate mofetil (MMF) may be similar to intravenous cyclophosphamide in treating lupus nephritis. However, these therapies have not been prospectively compared in childhood-onset lupus nephritis. Methods: In this prospective, multicenter, randomized trial, patients aged 5–17 years with proliferative lupus nephritis (class 3/4±5) and severely increased proteinuria (urine protein-creatinine ratio ≥1000 mg/g and/or 24-hour urinary protein excretion >25 mg/kg) were randomly assigned to receive either MMF or intravenous cyclophosphamide as initial therapy, alongside glucocorticoids. The primary end point was total renal response (TRR) at 24 weeks, with the aim of demonstrating the noninferiority of MMF compared with intravenous cyclophosphamide, using a noninferiority margin of 12%. TRR encompassed complete renal response, primary efficacy renal response, and partial renal response. Secondary end points assessed systemic disease activity and safety. Results: A total of 107 patients were enrolled from 17 hospitals, with 52 assigned to the MMF group (47 completed the 24-week therapy) and 55 assigned to the cyclophosphamide group (48 completed the 24-week therapy). In the intention-to-treat population, the TRR rate was 92% in the MMF group and 89% in the cyclophosphamide group (test for noninferiority, P = 0.008). In the per-protocol population, renal response was observed in 96% of patients in the MMF group versus 94% of patients in the cyclophosphamide group (test for noninferiority, P = 0.009). The difference in TRR rate between the MMF and cyclophosphamide groups was 3% (95% confidence interval, −9% to 15%) in the intention-to-treat population and 2% (95% confidence interval, −9% to 13%) in the per-protocol population. There were no significant differences in the incidence of adverse drug reactions between the MMF and cyclophosphamide groups in the intention-to-treat population (10% versus 15%, continuity correction chi-squared test, P = 0.44). Conclusions: After 24 weeks of therapy, oral MMF was noninferior to intravenous cyclophosphamide as initial therapy for childhood-onset proliferative lupus nephritis and exhibited a similar safety profile. Clinical Trial registry name and registration number: MMF versus cyclophosphamide in the Induction Therapy of Pediatric Active Proliferative lupus nephritis, ClinicalTrials.gov, NCT05495893.
- 12 September 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (3) , 560-568
Open AccessMycophenolate Mofetil versus Cyclophosphamide for Initial Therapy in Childhood-Onset Proliferative Lupus Nephritis
Key Points: The total renal response rate in the mycophenolate mofetil group was found to be noninferior to that in the cyclophosphamide group. There was no significant difference in the incidence of adverse drug reactions between the mycophenolate mofetil and cyclophosphamide groups. The reduction in SLE Disease Activity Index scores was similar between the two groups. Background: Recent studies suggest that oral mycophenolate mofetil (MMF) may be similar to intravenous cyclophosphamide in treating lupus nephritis. However, these therapies have not been prospectively compared in childhood-onset lupus nephritis. Methods: In this prospective, multicenter, randomized trial, patients aged 5–17 years with proliferative lupus nephritis (class 3/4±5) and severely increased proteinuria (urine protein-creatinine ratio ≥1000 mg/g and/or 24-hour urinary protein excretion >25 mg/kg) were randomly assigned to receive either MMF or intravenous cyclophosphamide as initial therapy, alongside glucocorticoids. The primary end point was total renal response (TRR) at 24 weeks, with the aim of demonstrating the noninferiority of MMF compared with intravenous cyclophosphamide, using a noninferiority margin of 12%. TRR encompassed complete renal response, primary efficacy renal response, and partial renal response. Secondary end points assessed systemic disease activity and safety. Results: A total of 107 patients were enrolled from 17 hospitals, with 52 assigned to the MMF group (47 completed the 24-week therapy) and 55 assigned to the cyclophosphamide group (48 completed the 24-week therapy). In the intention-to-treat population, the TRR rate was 92% in the MMF group and 89% in the cyclophosphamide group (test for noninferiority, P = 0.008). In the per-protocol population, renal response was observed in 96% of patients in the MMF group versus 94% of patients in the cyclophosphamide group (test for noninferiority, P = 0.009). The difference in TRR rate between the MMF and cyclophosphamide groups was 3% (95% confidence interval, −9% to 15%) in the intention-to-treat population and 2% (95% confidence interval, −9% to 13%) in the per-protocol population. There were no significant differences in the incidence of adverse drug reactions between the MMF and cyclophosphamide groups in the intention-to-treat population (10% versus 15%, continuity correction chi-squared test, P = 0.44). Conclusions: After 24 weeks of therapy, oral MMF was noninferior to intravenous cyclophosphamide as initial therapy for childhood-onset proliferative lupus nephritis and exhibited a similar safety profile. Clinical Trial registry name and registration number: MMF versus cyclophosphamide in the Induction Therapy of Pediatric Active Proliferative lupus nephritis, ClinicalTrials.gov, NCT05495893.
- Open Access
- 3 May 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-17
Calpain1 inhibition enhances autophagy-lysosomal pathway and ameliorates tubulointerstitial fibrosis in Nephronophthisis
Background: Nephronophthisis (NPH) is classified under the category of renal ciliopathies and is the most common genetic disease leading to renal failure in children. Early-onset and progressive renal tubulointerstitial fibrosis represents one of the most significant features, culminating in renal insufficiency. However, the molecular mechanism of tubulointerstitial fibrosis remains unclear. Previously, we constructed an NPH mouse model via CRISPR-Cas9. This mouse model demonstrated typical features of tubulointerstitial fibrosis. In this study, we aimed to explore the pathogenesis of tubulointerstitial fibrosis in NPH and identify early intervention targets in both the NPH models and patients. Methods: In this study, transcriptome changes in mouse kidneys were analyzed through RNA sequencing to explore the molecular mechanisms of renal tubulointerstitial fibrosis in NPH. We found an increased abundance of calpain1 in both the NPH models and patients. Pathway enrichment analysis indicated autophagy-lysosomal pathway was altered in the NPH models. Western blot, immunofluorescence or immunohistochemical staining were used to verify the expression of calpain1. We also detected autophagy activities in NPH models by lysotracker staining and transmission electron microscopy (TEM). Epithelial or mesenchymal-specific markers and Masson’s trichrome staining were used to detect the status of tubulointerstitial fibrosis. Furthermore, NPH models were treated with a calpain1 inhibitor to explore the role of calpain1 in autophagy-lysosomal pathway and tubulointerstitial fibrosis. Results: The increased abundance of calpain1 impaired the autophagy-lysosomal pathway and induced tubulointerstitial fibrosis by promoting epithelial-to-mesenchymal transition. On the other hand, calpain1 inhibition could enhance the autophagy-lysosomal pathway and ameliorate the phenotypes of tubulointerstitial fibrosis in NPH models. Conclusions: Calpain1-mediated autophagy-lysosomal pathway disorder may be an important cause of tubulointerstitial fibrosis in NPH. Calpain1 may have therapeutic implications for renal tubulointerstitial fibrosis.
- 3 May 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-17
Open AccessCalpain1 inhibition enhances autophagy-lysosomal pathway and ameliorates tubulointerstitial fibrosis in Nephronophthisis
Background: Nephronophthisis (NPH) is classified under the category of renal ciliopathies and is the most common genetic disease leading to renal failure in children. Early-onset and progressive renal tubulointerstitial fibrosis represents one of the most significant features, culminating in renal insufficiency. However, the molecular mechanism of tubulointerstitial fibrosis remains unclear. Previously, we constructed an NPH mouse model via CRISPR-Cas9. This mouse model demonstrated typical features of tubulointerstitial fibrosis. In this study, we aimed to explore the pathogenesis of tubulointerstitial fibrosis in NPH and identify early intervention targets in both the NPH models and patients. Methods: In this study, transcriptome changes in mouse kidneys were analyzed through RNA sequencing to explore the molecular mechanisms of renal tubulointerstitial fibrosis in NPH. We found an increased abundance of calpain1 in both the NPH models and patients. Pathway enrichment analysis indicated autophagy-lysosomal pathway was altered in the NPH models. Western blot, immunofluorescence or immunohistochemical staining were used to verify the expression of calpain1. We also detected autophagy activities in NPH models by lysotracker staining and transmission electron microscopy (TEM). Epithelial or mesenchymal-specific markers and Masson’s trichrome staining were used to detect the status of tubulointerstitial fibrosis. Furthermore, NPH models were treated with a calpain1 inhibitor to explore the role of calpain1 in autophagy-lysosomal pathway and tubulointerstitial fibrosis. Results: The increased abundance of calpain1 impaired the autophagy-lysosomal pathway and induced tubulointerstitial fibrosis by promoting epithelial-to-mesenchymal transition. On the other hand, calpain1 inhibition could enhance the autophagy-lysosomal pathway and ameliorate the phenotypes of tubulointerstitial fibrosis in NPH models. Conclusions: Calpain1-mediated autophagy-lysosomal pathway disorder may be an important cause of tubulointerstitial fibrosis in NPH. Calpain1 may have therapeutic implications for renal tubulointerstitial fibrosis.
- 6 April 2025
- Published by Elsevier in Cells & Development
- Vol. 182, 204025
Generation of kidney organoids derived from human expanded potential stem cells
- 6 April 2025
- Published by Elsevier in Cells & Development
- Vol. 182, 204025
Generation of kidney organoids derived from human expanded potential stem cells
- Open Access
- 24 February 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (3) , e70245
Kibra knockdown inhibits the aberrant Hippo pathway, suppresses renal cyst formation and ameliorates renal fibrosis in nphp1KO mice
Introduction: Nephronophthisis (NPH) is an autosomal recessive interstitial cystic kidney disease, which is the most common genetic cause of end‐stage renal disease (ESRD) in childhood. The Hippo pathway is regulated by the cilium and has been suggested to be linked to NPH. The aim of the study was to investigate the involvement of Hippo pathway in the pathogenesis of nphp1 defect‐associated NPH (NPH1).Method: Nphp1 knockout (nphp1KO) Madin‐Darby Canine Kidney (MDCK) cells and nphp1KO C57BL/6J mice were generated via CRISPR gene editing strategy. The siRNAs targeting Kibra, MST1 and LATS1 were designed. An AAV9 vector was designed for Kibra knockdown. The expression and phosphorylation of core Hippo pathway molecules were evaluated. Pathological renal changes were evaluated via light microscopy respectively with haematoxylin–eosin and Masson staining.Results: In nphp1KO MDCK cells, nphp1KO mice and NPH1 patients’ kidneys, Kibra, p‐MST1/2, p‐LATS and p‐YAP exhibited a notable increase in levels, with an even greater elevation observed in renal cyst cells, indicating the Hippo pathway activated in these nphp1‐deficient contexts. Nphp1 re‐expression reversed the Hippo pathway activation in cells, indicating that the Hippo pathway activation is related to nphp1 deficiency in vitro. Meanwhile, in vitro, MST1 knockdown downregulated LATS1 and YAP phosphorylation, LATS1 knockdown downregulated YAP phosphorylation, suggesting the activation of the canonical Hippo pathway in nphp1‐deficient contexts. Knockdown of the upstream regulator Kibra inhibited the Hippo pathway activation in both nphp1KO MDCK cells and mice. Following Kibra knockdown, the organisation of nphp1KO MDCK cells became more compact, the intensity of the actin fibres increased. Besides, decreased renal fibrosis and cyst formation were observed in nphp1KO mice.Conclusions: The canonical Hippo pathway is aberrantly activated in nphp1‐deficient conditions. Kibra may serve as a crucial upstream regulator of nphp1 deficiency‐related Hippo pathway activation. Kibra upregulation and activation of the Hippo pathway are involved in the pathogenesis of NPH1.Key Points: Canonical Hippo pathway activated in nphp1‐deficient disease models and patients. Kibra was a key upstream molecule in regulating the activation of canonical Hippo pathway in nphp1‐deficient disease models and patients and closely related to renal cyst formation and fibrosis in nphp1KO mice.
- 24 February 2025
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (3) , e70245
Open AccessKibra knockdown inhibits the aberrant Hippo pathway, suppresses renal cyst formation and ameliorates renal fibrosis in nphp1KO mice
Introduction: Nephronophthisis (NPH) is an autosomal recessive interstitial cystic kidney disease, which is the most common genetic cause of end‐stage renal disease (ESRD) in childhood. The Hippo pathway is regulated by the cilium and has been suggested to be linked to NPH. The aim of the study was to investigate the involvement of Hippo pathway in the pathogenesis of nphp1 defect‐associated NPH (NPH1).Method: Nphp1 knockout (nphp1KO) Madin‐Darby Canine Kidney (MDCK) cells and nphp1KO C57BL/6J mice were generated via CRISPR gene editing strategy. The siRNAs targeting Kibra, MST1 and LATS1 were designed. An AAV9 vector was designed for Kibra knockdown. The expression and phosphorylation of core Hippo pathway molecules were evaluated. Pathological renal changes were evaluated via light microscopy respectively with haematoxylin–eosin and Masson staining.Results: In nphp1KO MDCK cells, nphp1KO mice and NPH1 patients’ kidneys, Kibra, p‐MST1/2, p‐LATS and p‐YAP exhibited a notable increase in levels, with an even greater elevation observed in renal cyst cells, indicating the Hippo pathway activated in these nphp1‐deficient contexts. Nphp1 re‐expression reversed the Hippo pathway activation in cells, indicating that the Hippo pathway activation is related to nphp1 deficiency in vitro. Meanwhile, in vitro, MST1 knockdown downregulated LATS1 and YAP phosphorylation, LATS1 knockdown downregulated YAP phosphorylation, suggesting the activation of the canonical Hippo pathway in nphp1‐deficient contexts. Knockdown of the upstream regulator Kibra inhibited the Hippo pathway activation in both nphp1KO MDCK cells and mice. Following Kibra knockdown, the organisation of nphp1KO MDCK cells became more compact, the intensity of the actin fibres increased. Besides, decreased renal fibrosis and cyst formation were observed in nphp1KO mice.Conclusions: The canonical Hippo pathway is aberrantly activated in nphp1‐deficient conditions. Kibra may serve as a crucial upstream regulator of nphp1 deficiency‐related Hippo pathway activation. Kibra upregulation and activation of the Hippo pathway are involved in the pathogenesis of NPH1.Key Points: Canonical Hippo pathway activated in nphp1‐deficient disease models and patients. Kibra was a key upstream molecule in regulating the activation of canonical Hippo pathway in nphp1‐deficient disease models and patients and closely related to renal cyst formation and fibrosis in nphp1KO mice.
- Open Access
- 31 July 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 563, 119898
A CD3G homozygous pathogenic variant in a Chinese child with lupus-like disease, autoimmune thyroiditis and immunodeficiency
- 31 July 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 563, 119898
Open AccessA CD3G homozygous pathogenic variant in a Chinese child with lupus-like disease, autoimmune thyroiditis and immunodeficiency